Needham & Company LLC Reaffirms “Buy” Rating for Autolus Therapeutics (NASDAQ:AUTL)

Needham & Company LLC restated their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTL) in a research report released on Friday morning, Benzinga reports. They currently have a $9.00 target price on the stock.

Separately, Truist Financial boosted their price target on Autolus Therapeutics from $10.00 to $11.00 and gave the company a buy rating in a report on Tuesday, April 9th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Autolus Therapeutics presently has a consensus rating of Moderate Buy and an average price target of $8.16.

Autolus Therapeutics Trading Down 2.4 %

AUTL opened at $4.90 on Friday. The company has a market cap of $1.30 billion, a P/E ratio of -4.12 and a beta of 1.90. The business’s 50-day moving average price is $6.01 and its 200-day moving average price is $5.06. Autolus Therapeutics has a 12 month low of $1.61 and a 12 month high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Thursday, March 14th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.18). Equities research analysts forecast that Autolus Therapeutics will post -0.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in AUTL. UBS Group AG boosted its position in shares of Autolus Therapeutics by 2.8% in the 4th quarter. UBS Group AG now owns 84,655 shares of the company’s stock worth $545,000 after purchasing an additional 2,345 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of Autolus Therapeutics by 337.3% in the 4th quarter. BNP Paribas Financial Markets now owns 4,268 shares of the company’s stock worth $27,000 after purchasing an additional 3,292 shares in the last quarter. Cetera Investment Advisers boosted its position in shares of Autolus Therapeutics by 2.9% in the 1st quarter. Cetera Investment Advisers now owns 141,600 shares of the company’s stock worth $261,000 after purchasing an additional 4,000 shares in the last quarter. EWA LLC boosted its position in shares of Autolus Therapeutics by 40.2% in the 4th quarter. EWA LLC now owns 25,678 shares of the company’s stock worth $155,000 after purchasing an additional 7,361 shares in the last quarter. Finally, LPL Financial LLC boosted its position in shares of Autolus Therapeutics by 39.2% in the 4th quarter. LPL Financial LLC now owns 32,300 shares of the company’s stock worth $61,000 after purchasing an additional 9,100 shares in the last quarter. Hedge funds and other institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.